CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 50 enrolled
Drug / intervention
Pioglitazone+Citalopram+Chlordiazepoxide +1 moredrug
Likely dose
Pioglitazone+Citalopram+Chlordiazepoxide 15 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01109030
NCT01109030Phase 3Completed

Pioglitazone as an Adjunct for Moderate to Severe Depressive Disorder

Tehran University of Medical Sciences·interventional·Posted Apr 22, 2010·Updated May 9, 2012

In Brief

A Phase 3 clinical trial evaluating Pioglitazone+Citalopram+Chlordiazepoxide and Placebo+ Citalopram+ Chlordiazepoxide for Major Depressive Disorder. Completed, enrolled 50 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether Pioglitazone as an adjunct to Citalopram is effective in treatment of moderate to severe depression

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesIran
Collaborators--

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 22, 2010
Enrollment StartApr 1, 2010
Primary CompletionOct 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 16.2 years ago

Interventions

Pioglitazone+Citalopram+Chlordiazepoxidedrug

Pioglitazone 15 mg every 12 hours for six weeks Citalopram 20 mg per day for week one, and then 30 mg/day for 5 consecutive weeks. Chlordiazepoxide 10 mg each night for first three weeks

Placebo+ Citalopram+ Chlordiazepoxidedrug

Placebo 1 Q12h for 6 weeks with the same shape and color as Pioglitazone. Citalopram 20 mg per day for week one, and then 30 mg/day for 5 consecutive weeks. Chlordiazepoxide 10 mg each night for first three weeks